

Research article

Open Access

Characterisation of methionine adenosyltransferase from *Mycobacterium smegmatis* and *M. tuberculosis*

Bradley J Berger* and Marvin H Knodel

Address: Chemical & Biological Defence Section, Defence R&D Canada – Suffield, PO Box 4000, Medicine Hat, AB, T1A 8K6, Canada

Email: Bradley J Berger* - Brad.Berger@drdc-rddc.gc.ca, Marvin H Knodel - Marvin.Knodel@drdc-rddc.gc.ca

* Corresponding author

Published: 16 June 2003

Received: 08 April 2003

BMC Microbiology 2003, 3:12

Accepted: 16 June 2003

This article is available from: <http://www.biomedcentral.com/1471-2180/3/12>

© 2003 Berger and Knodel, licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: Tuberculosis remains a serious world-wide health threat which requires the characterisation of novel drug targets for the development of future antimycobacterials. One of the key obstacles in the definition of new targets is the large variety of metabolic alterations that occur between cells in the active growth and chronic/dormant phases of tuberculosis. The ideal biochemical target should be active in both growth phases. Methionine adenosyltransferase, which catalyses the formation of S-adenosylmethionine from methionine and ATP, is involved in polyamine biosynthesis during active growth and is also required for the methylation and cyclopropylation of mycolipids necessary for survival in the chronic phase.

Results: The gene encoding methionine adenosyltransferase has been cloned from *Mycobacterium tuberculosis* and the model organism *M. smegmatis*. Both enzymes retained all amino acids known to be involved in catalysing the reaction. While the *M. smegmatis* enzyme could be functionally expressed, the *M. tuberculosis* homologue was insoluble and inactive under a large variety of expression conditions. For the *M. smegmatis* enzyme, the V_{max} for S-adenosylmethionine formation was 1.30 $\mu\text{mol}/\text{min}/\text{mg}$ protein and the K_m for methionine and ATP was 288 μM and 76 μM respectively. In addition, the enzyme was competitively inhibited by 8-azaguanine and azathioprine with a K_i of 4.7 mM and 3.7 mM respectively. Azathioprine inhibited the in vitro growth of *M. smegmatis* with a minimal inhibitory concentration (MIC) of 500 μM , while the MIC for 8-azaguanine was >1.0 mM.

Conclusion: The methionine adenosyltransferase from both organisms had a primary structure very similar to those previously characterised in other prokaryotic and eukaryotic organisms. The kinetic properties of the *M. smegmatis* enzyme were also similar to known prokaryotic methionine adenosyltransferases. Inhibition of the enzyme by 8-azaguanine and azathioprine provides a starting point for the synthesis of higher affinity purine-based inhibitors.

Background

Tuberculosis represents one of the world's greatest sources of mortality and morbidity, with approximately 8 million new infections and 2 million deaths per year [1]. The situation regarding the control of tuberculosis has signifi-

cantly worsened over the last decade, with the spread of strains resistant to multiple antimycobacterial agents. There is a profound need for the identification and development of novel chemotherapeutic compounds against tuberculosis. The characterisation of mycobacterial

biochemical pathways aids this process through the identification of enzymes amenable to therapeutic inhibition.

Mycobacterium tuberculosis is difficult to kill for a number of reasons. The organism is surrounded by a dense waxy coat consisting of unusual long-chain fatty acids (mycolipids) with hydroxyl, methyl, and cyclopropyl substitutions that prevent many common antibiotics from entering the cell [2]. In addition, the organism normally resides in the unfused lysosome of macrophages, which further complicates access by antibiotics. Finally, the bacterium is able to enter a very slow-growing, chronic phase, where many biochemical targets are down-regulated [3]. In this state, the bacteria shift their metabolic focus from sugars to β -oxidation of fatty acids, which entails a down-regulation of glycolysis and an up-regulation of the glyoxylate shunt [4]. Therefore, in order to cure tuberculosis, an active compound must penetrate the macrophage, the bacterial coat, and be active against both the acute and chronic growth phases. For these reasons, antimycobacterial therapy relies on the combination of several drugs.

In the examination of biochemical pathways in *Mycobacterium tuberculosis*, it would be ideal to identify processes where an enzyme plays a role in both active and chronic phase survival. In active, replicative growth cells require polyamines for cell division. While the exact function of these molecules is unknown, it is hypothesised that the positively charged spermidine and spermine act to stabilise DNA during unwinding and strand separation [5]. In mycobacteria, polyamines may also play a role in transcriptional regulation [6], and have also been targeted for chemotherapeutic intervention [7,8]. In the biosynthesis of polyamines, decarboxylated S-adenosylmethionine acts as an aminopropyl donor for the formation of spermidine from putrescine, and of spermine from spermidine (Figure 1). These reactions give rise to methylthioadenosine, which can be recycled back to adenine and methionine for further synthesis of S-adenosylmethionine (SAM).

Several studies have shown that mycolipid biosynthesis is essential for survival of *M. tuberculosis* in the chronic growth phase [9,10]. Tuberculosis has been found to contain numerous genes encoding methyltransferases which methylate and cyclopropylate mycolic acids [11,12]. The methyltransferases use S-adenosylmethionine as a substrate, yielding S-adenosylhomocysteine as a byproduct for recycling (Figure 1). In a recent study, deletion of the *pcaA* gene, which is involved in cyclopropane formation in mycolic acids, led to an inability of *M. tuberculosis* to persist within and kill mice [10]. The mutant bacteria were able to grow normally and establish an infection, but were progressively eliminated from the spleen. Therefore,

mycolic acid biosynthesis provides an attractive target for the persistent stage of tuberculosis.

In the convergence of these active and chronic growth requirements is the enzyme methionine adenosyltransferase (MAT; also known as S-adenosylmethionine synthetase), which converts methionine and ATP to S-adenosylmethionine. Effective inhibition of this enzyme could then impact both growth phases of the organism. In this study, we have identified, cloned, functionally expressed, and characterised the methionine adenosyltransferase from the model organism *M. smegmatis*. In addition, the *M. tuberculosis* homologue has been cloned. Several prototypic inhibitors have been examined against the recombinant *M. smegmatis* enzyme.

Results

Methionine Adenosyltransferase in *Mycobacterium* spp

The complete, published genome for *Mycobacterium tuberculosis* H37Rv contains a single gene with very high homology to a variety of bacterial and eukaryotic MAT [13]. The gene, designated Rv1392 is listed as a putative MAT, but has not yet been cloned, expressed, or characterised. The more recent complete, published genome for *M. tuberculosis* CDC1551 contains an identical gene designated MT1437 [14]. The function of this gene has likewise not been validated. Similarly, there are no published reports on the characterisation of MAT activity in any mycobacterial system.

Through examination of the complete, published genome of *M. leprae* [15], and the on-going genome projects for *M. bovis*, *M. smegmatis*, *M. avium*, and *M. marinum* it was possible to discover a single gene in each organism with a very high identity to Rv1392. Together with all other published MAT sequences available from the Entrez database <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Protein>, the putative mycobacterial MAT were aligned and a cladogram constructed using the Neighbor joining method [16] (Figure 2). The relationship of the mycobacterial sequences mimicked the phylogeny of the organisms as determined by their rRNA gene sequences (data not shown). The *M. tuberculosis* and *M. bovis* MAT sequences were identical and closely related to *M. marinum* (95%). The *M. tuberculosis* sequence was then more distantly related to *M. leprae* (91%), *M. avium* (92%), and *M. smegmatis* (87%). As a group, the mycobacterial enzymes clustered with MAT from *Streptomyces* spp (72–73% identical), and *Corynebacterium glutamicum* (66%), and had a more distant relationship with *Aquifex aeolicus* (42%), *Thermotoga maritima* (63%), and the low G+C content Gram-positive bacteria (38–58%). The *M. tuberculosis* MAT sequence was 49% identical to that from *E. coli*, 50% to *Saccharomyces cerevisiae*, 46% to *Plasmodium falciparum*, 49% to *Arabidopsis thaliana*, and 47% to *Homo sapiens*.




Figure 1

S-Adenosylmethionine as a common biochemical substrate for the rapid and chronic growth stages of *M. tuberculosis*.

The pathways of S-adenosylmethionine usage and the potential recycling routes of methionine and ATP are shown. The enzymes which catalyse the reactions are: 1 methionine adenosyltransferase, 2 S-adenosylmethionine decarboxylase, 3 spermidine/spermine aminopropyltransferase, 4 methylthioadenosine phosphorylase, 4a methylthioadenosine nucleosidase, 4b methylthioribose kinase, 5 four steps not shown, 6 aminotransferase, 7 mycolic acid methyltransferases, 8 S-adenosylhomocysteine nucleosidase, 8a S-adenosylhomocysteine hydrolase, 8b S-ribosylhomocysteine hydrolase, and 9 methionine synthetase. It has not yet been determined in *M. tuberculosis* whether enzyme 4 or 4a/4b, and 8 or 8a/8b catalyses the recycling of methionine. The exact aminotransferase catalysing step 6 has also not been elucidated.

The high level of sequence identity seen between the *M. tuberculosis* MAT sequence and those from widely divergent organisms was consistent with the high degree of sequence conservation found across all MAT. In Figure 3, an alignment of selected MAT sequences is shown, along with annotation relating to the alignment of all the sequences shown in Figure 1. As can be seen with the ten sequences in Figure 3, there was high identity across bacterial and eukaryotic MAT. There were thirteen residues conserved across all 117 sequences used for Figure 2, but this value increased to 55 residues when the threshold is dropped to 98% conservation in order to allow for

sequencing errors in genome data. All of the mycobacterial MAT sequences were found to retain the residues implicated in substrate and cofactor binding in the *E. coli* MAT crystal structure [17]. D31(D17) and D309(D272) are the Mg^{2+} cofactor binding sites, while E57(E43) is the K^+ cofactor binding site. D147(D119) and D276(239) interact with the methionine substrate, and G297(G260) through D304(D267) form the P-loop motif that make up the binding site for the ATP substrate [17]. The residue numbers represent the position in the alignment shown in Figure 3. The numbers in parentheses represent the corresponding residues in the *E. coli* MAT, which has been

structurally determined by X-ray crystallography [29]. MAT is known from the *E. coli* structural model to form pairs of homodimers where the substrate binding sites are made up of the appropriate interface residues from each monomer [17]. Based on the close primary sequence identity to the *E. coli* MAT, the mycobacterial enzymes would be expected to have a very similar spatial arrangement.

Cloning and Expression of Methionine Adenosyltransferases

The putative gene encoding MAT was cloned from both *M. tuberculosis* H37Rv and from *M. smegmatis* NCTC-8159. The sequences were then initially subcloned into pCALN-FLAG in order to make N-terminal calmodulin-binding peptide fusion proteins. The enzymes were expressed in *E. coli* BL21 CodonPlus RIL cells under the conditions outlined in the Methods section. The *M. tuberculosis* MAT was found to express completely as insoluble, inactive inclusion bodies, whereas the *M. smegmatis* enzyme yielded primarily inactive inclusions with approximately 5% soluble, active enzyme. By scaling up the incubations, sufficient *M. smegmatis* MAT was obtained for further characterisation.

In order to produce soluble, active *M. tuberculosis* MAT, a number of alternative methodologies were applied. The inclusion bodies were solubilised with 8 M urea and subjected to refolding by dialysis exactly as outlined in Lopez-Vara et al [18]. Inclusion bodies were also solubilised using N-laurylsarcosine at pH 11 and refolded as outlined in the Novagen refolding kit. Expression of the protein was attempted at different temperatures, with different concentrations of IPTG, and for different lengths of time post-induction. Induction was performed on stationary phase cells. The pCALNFLAG construct was used in *E. coli* BL21(DE3)pLysS for more stringent regulation of induction [19], or in BL21(DE3)Origami which maintains a more oxidizing internal environment to allow for disulfide formation [20]. The MAT sequence was fused to a decahistidine N-terminal tag or to an N-terminal fusion with the *E. coli* NusA protein which is reported to increase solubility [21]. Finally, the tuberculosis enzyme was cloned into pWH1520 for expression in *Bacillus megaterium* under the xylose operon [22]. None of these experiments yielded active MAT. However, solubilisation of inclusion bodies by N-laurylsarcosine as per the Novagen refolding kit did yield soluble enzyme under physiological conditions. Unfortunately, the micelles containing the enzyme were precipitated by the addition of Mg²⁺, preventing activation of the apoenzyme. In addition, fusion of the tuberculosis MAT to the *E. coli* NusA protein also resulted in large amounts of soluble protein. However, neither the fusion protein nor the enterokinase-liberated MAT had detectable activity. The basis for this lack of

activity is not clear, but may be due to misfolding of the fusion protein.

Characterisation and Inhibition of *M. smegmatis* Methionine Adenosyltransferase

The *M. smegmatis* MAT was examined with variable concentrations of substrate and a fixed concentration of cosubstrate and cofactors in order to determine the kinetic constants for the enzyme (Figure 4). The V_{max} for the enzyme was found to be 1.30 ± 0.40 μmol/min/mg protein and the K_m was 288.47 ± 40.90 μM for methionine and 76.19 ± 13.53 μM for ATP. The calculated K_{cat} for the enzyme was 0.93 s⁻¹, and the K_{cat}/K_m was 12200 M⁻¹s⁻¹ for ATP and 3200 M⁻¹s⁻¹ for methionine.

In order to screen substrate analogues as potential inhibitors, commercially available test compounds were screened initially in 10-fold excess to the substrate concentration, without enzyme-inhibitor preincubation. Eleven methionine analogues (Table 1) and 33 purine analogues (Table 2) were screened in this manner. Of the methionine analogues, no compound inhibited the production of SAM by more than 25%. The best of these inhibitors, cycloleucine, is treated in the literature as a classic inhibitor of MAT activity, but typically acts weakly [23]. Of the purine analogues, two compounds provided substantial inhibition of MAT activity: 8-azaguanine at 82% inhibition and azathioprine at 76%. These two compounds were then tested in detail in order to determine the inhibition constants (Figure 5). Both purine analogues yielded an inhibition pattern consistent with competitive inhibition, and 8-azaguanine was found to have a calculated K_i of 4.70 ± 0.77 mM and azathioprine one of 3.74 ± 1.00 mM. These K_i values are 49–62 times greater than the K_m of the enzyme for ATP.

The two inhibitors were also tested for their ability to inhibit the *in vitro* growth of *M. smegmatis* in Middlebrook 7H9 medium. Azathioprine was found to have an MIC of 500 μM, while 8-azaguanine was unable to completely inhibit growth up to 1.0 mM. Both compounds had a marked effect on growth (at least 50% growth inhibition) down to 2.0 μM.

Discussion

S-Adenosylmethionine is one of the most important cellular biochemical cofactors, and plays a role in a large variety of essential metabolic pathways. The formation of SAM from methionine and ATP by MAT therefore represents a crucial checkpoint for numerous functions required for cell growth and division, such as polyamine biosynthesis and methylation reactions. Not surprisingly, MAT is a very highly conserved enzyme and displays a high sequence identity from bacteria through to humans. Even bacteria with known degenerate, minimal genomes,




Figure 4

Kinetic characterisation of *M. smegmatis* methionine adenosyltransferase. The enzyme was incubated with 0 – 4.0 mM substrate and 10 mM cosubstrate as described in the Methods section. The production of SAM was measured by HPLC, and the resulting data fitted to the Michaelis-Menton equation.

such as *Mycoplasma spp* [24,25], *Buchnera aphidocola* [26], and *Mycobacterium leprae* [15] contain a sequence with a high identity to MAT. The only exception to the ubiquity of MAT is the archaeobacteria, which perform this enzymatic function with a highly divergent enzyme which shares only the active site residues with the *E. coli* MAT [27]. It is not presently clear whether the archaeal enzymes represent convergent or divergent evolution, but the close identity within the bacterial/eukaryotic MAT would suggest that the archaeal enzyme is analogous.

In mycobacteria, SAM plays an additional role beyond normal cellular methylation and aminopropylation reactions, as the organisms are reliant on the cofactor for the formation of methylated and cyclopropylated mycolic acids. These fatty acids are very long, and consist of 70–90 carbons [2] and contain methyl, hydroxyl, and cyclopropyl substitutions that are diagnostic for individual mycobacterial species [28]. In *M. tuberculosis*, there are as many as seven SAM-dependent methyltransferases involved in mycolic acid methylation and cyclopropylation [13]. Interference with cyclopropyl formation in mycolic acid

synthesis has been shown to impact virulence, persistence, and resistance of *M. tuberculosis* to oxidative stress [10]. When coupled with the role of SAM as an aminopropyl donor for polyamine biosynthesis during cell division [5], interference with SAM has the potential to impact both the active and persistent phases of tuberculosis. The obvious convergence of these biochemical pathways is the synthesis of SAM by MAT.

In this paper, we have cloned the *M. tuberculosis* and *M. smegmatis* MAT, and have found that the sequences display a high degree of identity with other bacterial and eukaryotic MAT. Both organisms contain only one copy of MAT which are 87% identical. However, the 13% difference in primary sequence had a major impact on the functional expression of the enzymes. The *M. smegmatis* MAT expressed in *E. coli* primarily as inclusion bodies, although 5–20% of the enzyme could be recovered as soluble, active material depending on the length of time of induction. The *M. tuberculosis* MAT expressed in *E. coli* solely as inclusion bodies. A large number of experimental variations and refolding experiments were attempted,




Figure 5
Inhibition of methionine adenosyltransferase by 8-azaguanine and azathioprine. The *M. smegmatis* enzyme was incubated with 0–10 mM inhibitor, 10 mM methionine, and 0.5 (squares), 1.0 (circles), 2.0 (inverted triangles), or 3.0 (triangles) mM ATP as described in the Methods section. The data is shown as Dixon plots.

Table 1: The inhibition of methionine adenosyltransferase by methionine analogues. The *M. smegmatis* enzyme was incubated with 1 mM methionine, 10 mM ATP, 20 mM Mg²⁺, 150 mM K⁺, and 10 mM inhibitor, as described in the Methods section.

Inhibitor	Inhibition (%)	Inhibitor	Inhibition (%)
α -Methyl-DL-methionine	18.8 ± 3.7	3-Methylthio propionaldehyde	18.4 ± 3.7
L-Methionine sulfoxide	4.0 ± 0.8	L-Methionine methyl ester	17.7 ± 3.5
L-Methionine sulfone	9.2 ± 1.8	L-Penicillamine	15.0 ± 3.0
Cycloleucine	25.8 ± 5.1	L-Methionine sulfoximine	12.6 ± 2.5
L-Ethionine	20.4 ± 4.1	(R)-Methioninol	0.0 ± 0.0
L-Methioninamide	23.9 ± 4.8		

but active tuberculosis MAT could not be recovered. In two instances, the enzyme was obtained in soluble form under physiological conditions, but still retained a lack of activity. The solution to this difficulty is still under examination.

The *M. smegmatis* MAT was characterised and found to have a V_{max} of 1.30 μ mol/min/mg protein, and a K_m for

methionine of 288 μ M and for ATP of 76 μ M. These values are interesting when compared to similar values found for other MAT. In general, the K_m for methionine is lower than the K_m for ATP. In a MAT purified from human lymphocytes, the K_m was 31 μ M for methionine and 84 μ M for ATP [29], while in bovine brain the K_m was 10 μ M for methionine and 50 μ M for ATP [30]. In *Leishmania infantum*, the K_m was 35 μ M for methionine and 5 mM for ATP.

Table 2: The inhibition of methionine adenosyltransferase by purine analogues. The *M. smegmatis* enzyme was incubated with 1 mM ATP, 10 mM methionine, 20 mM Mg²⁺, 150 mM K⁺, and 10 mM inhibitor, as described in the Methods section.

Inhibitor	Inhibition (%)	Inhibitor	Inhibition (%)
8-Chlorotheophylline	70 ± 4.1	1,3,7-Trimethyluric acid	0.0 ± 0.0
7-Hydroxypropyl theophylline	16.1 ± 4.0	6-Bromopurine	31.4 ± 1.5
Uric acid	45.6 ± 11.9	7-Methylxanthine	36.3 ± 4.2
Xanthine	35.4 ± 2.5	1-Methylxanthine	35.9 ± 5.8
8-Azaguanine	81.7 ± 2.8	2-Hydroxypurine	33.8 ± 0.6
3,7-Dimethyluric acid	27.9 ± 1.6	6-Chloropurine	31.4 ± 7.3
2,6-Dichloropurine	35.5 ± 6.9	2-Amino-6-chloropurine-9-acetic acid	23.5 ± 8.4
6-Mercaptopurine	40.1 ± 2.3	6-Benzoyloxypurine	17.7 ± 3.4
1-Methyluric acid	43.4 ± 2.9	2-Aminopurine	11.0 ± 2.1
Purine riboside	44.4 ± 5.9	6-Methylpurine	0.0 ± 0.0
O-Methylguanine	60.3 ± 5.3	7-Methyluric acid	11.4 ± 2.2
2,6-Diaminopurine	29.3 ± 7.9	6-Cyanopurine	24.2 ± 4.6
2-Amino-6-carboxy ethyl mercaptopurine	31.9 ± 9.8	2-Amino-6-chloropurine riboside	17.2 ± 3.3
6-Propoxyurine	27.9 ± 4.0	6-Dimethyl aminopurine	28.0 ± 5.3
6-Dimethylallyl aminopurine riboside	41.6 ± 5.5	Azathioprine	75.5 ± 5.4
8-Aza-2,6-diaminopurine	40.0 ± 2.2	6-Mercaptopurine riboside	30.0 ± 5.7
6-Chloropurine riboside	17.1 ± 3.5		

[31], whereas in *Trypanosoma brucei brucei* there were two isoforms detectable with Km values of 20 μM and 200 μM for methionine, and 53 μM and 1.75 mM for ATP [32]. In *E. coli*, these values were much more similar, with a Km of 80 μM for methionine and 110 μM for ATP [33]. The *M. smegmatis* MAT is thus unusual in that the Km for ATP is significantly lower than that for methionine. The molecular basis and implication of this difference in substrate affinity is unclear, but, in general, the Km values for the mycobacterial MAT are in the same range as in other characterised organisms. Aside from the Km value for methionine, the *M. smegmatis* MAT appeared to closely resemble the *E. coli* enzyme. In *E. coli*, the Vmax was found to be 2.2 μmol/min/mg protein, the Kcat 1.53 s⁻¹, and the Kcat/Km for ATP 13900 M⁻¹s⁻¹ [33]. The corresponding *M. smegmatis* values were 1.30 μmol/min/mg protein, 0.93 s⁻¹, and 12200 M⁻¹s⁻¹. Therefore, the considerable data available on the structure of the *E. coli* enzyme should be of direct relevance for ligand binding studies using the mycobacterial enzyme [17].

The *M. smegmatis* enzyme was also screened with a number of commercially available methionine and purine analogues in order to discover potential inhibitors. None of the methionine analogues had appreciable activity, while two of the purine analogues, 8-azaguanine and azathioprine (Figure 6), were effective inhibitors. Detailed kinetic characterisation of these inhibitors demonstrated that both acted competitively and both had Ki values around 4 mM. Despite these high Ki values, both compounds inhibited growth of *M. smegmatis* in vitro, with

growth inhibition exceeding 50% down to 2.0 μM. Azathioprine was also able to completely inhibit *M. smegmatis* growth with an MIC of 500 μM, while the MIC for 8-azaguanine was >1.0 mM. However, both compounds are known to have toxic, carcinogenic, or immunosuppressive properties [34–37], which make them unsuitable as candidate drugs against tuberculosis in vivo. Nevertheless, these two purine analogues represent a suitable starting point for the design of more effective and tolerable inhibitors of MAT activity. Although the compounds tested in Table 2 are too dissimilar to allow for a detailed structure-activity analysis, one key observation can be obtained. The two most effective inhibitors have no structural alterations in common beyond substitution of the 2-amino position in the purine ring. 8-Aza-2,6-diaminopurine was a much poorer inhibitor than 8-azaguanine, suggesting that the aza-substitution at position 8 was less important for activity. O-Methylguanine, on the other hand, inhibited SAM formation by 60%, highlighting again the substitution in position 2. Azathioprine has a large group substituted in this position, which might be amenable to synthetic alteration for testing novel inhibitors. Azathioprine has been used clinically as an immunosuppressant and anti-arthritic agent, but has not been previously examined as an antimicrobial agent. Further examination of structural analogues may be useful.

Given the central role of SAM in cell growth and division, it is unsurprising that MAT has been examined as a molecular target for the development of anticancer agents. Most of the methionine and purine analogues studied have




Figure 6
The structures of 8-azaguanine and azathioprine. From right to left: the adenine portion of ATP, 8-azaguanine, and azathioprine.

been fairly poor inhibitors. For example, cycloleucine, which is often treated as a classic inhibitor of MAT activity, only has a K_i of 10 mM against human MAT [23]. Similarly, four other cyclic analogues of methionine had K_i values of 0.75–3.0 mM against rat liver MAT [38]. Of thirteen methylmethionine analogues, the best three compounds had K_i values ranging from 0.5–2.4 mM, while most had little inhibitory effect [39]. In terms of methionine analogues, the best inhibitors found to date appear to be a series of epithio and epoxy analogues of the amino acid, where the K_i against rat liver MAT was 7–105 μ M [40]. A series of ATP-methionine and ATP-homocysteine adducts, which resemble the transition state of the substrates, have also been synthesized and studied [41,42]. Of these compounds, several had submicromolar K_i values against rat liver MAT. Clearly, with synthetic optimisation, it is possible to generate effective inhibitors of MAT.

Conclusions

Methionine adenosyltransferase has been cloned from *M. tuberculosis* and *M. smegmatis*. The enzymes have been found to retain all amino acids known from *E. coli* to be involved in catalysing the formation of S-adenosylmethionine. The *M. smegmatis* enzyme was functionally expressed, while that from *M. tuberculosis* was insoluble and inactive under a large variety of conditions. The *M. smegmatis* MAT has kinetic constants for methionine and ATP that are very similar to previously characterised enzymes, and can be inhibited by 8-azaguanine and azathioprine. The latter compound was also found to inhibit *M. smegmatis* growth in vitro with an MIC of 500 μ M. This

finding opens up the potential for the development of more potent inhibitors of mycobacterial MAT.

Methods

Cells and Reagents

Mycobacterium tuberculosis H37Rv was obtained from Dr J. Talbot, University of Alberta, and *Mycobacterium smegmatis* NCTC-8159 (Cornell 3) from the National Culture Type Collection (Central Public Health Laboratory, London, UK). Both organisms were grown in Middlebrook 7H9 liquid medium or on Middlebrook 7H10 agar plates (Sigma Chemical Co., Oakville, ON, CA) at 37°C. All substrates and inhibitors were obtained from Sigma Chemical Co., Aldrich Chemical Co. (Oakville, ON, CA), or Fluka (Oakville, ON, CA).

Cloning and Functional Expression

Genomic DNA was isolated from cells by vortexing packed cells in a minimal volume of 50 mM Tris-HCl pH 8.0/10 mM EDTA/100 mM NaCl containing 500 μ M acid washed glass beads (Sigma Chemical Co.). After allowing the glass beads to settle, the supernatant was added to an equal volume of 10 mM Tris-HCl pH 8.0/100 mM NaCl/25 mM EDTA/0.5% w/v sodium dodecyl sulfate/0.1 mg/ml proteinase K and incubated for 1 hr at 37°C with occasional gentle mixing. The mixture was then subjected to extraction with phenol and chloroform isoamyl alcohol (24:1), and the DNA ethanol precipitated.

The nucleotide sequences of the putative MAT genes were obtained by BLAST analysis [43] of the completed *M. tuberculosis* H37Rv genome data ([13], <http://>

www.sanger.ac.uk/Projects/M_tuberculosis) and the incomplete *M. smegmatis* mc²155 genome data <http://www.tigr.org/tdb/mdb/mdbinprogress.html> In both cases, a single high-homology open reading frame was identified and used for the design of oligonucleotide primers For *M. tuberculosis*, the 5' primer was GACGAC-GACAAGATGAGCGAAAAGGGTCGGCTG and the 3' primer GGAACAAGACCCGCTCTAGATGGCGCGCTT-GAGG, while for *M. smegmatis* the 5' primer was GAC-GACGACAAGATGAGCAAAGGTCCGCTGTTA and the 3' primer GGAACAAGACCCGTTTCAGATGGCGGACT-TCAGG Both sets of primers contained a 5' 12 nucleotide LIC (ligation independent cloning, [44]) sequence and an in-frame start codon, and the 3' primers contained a 13 nucleotide LIC sequence and an in-frame stop codon The target sequences were amplified from the genomic DNA using Taq polymerase (Promega, Madison, WI, USA), 1.5 mM MgCl₂, 200 μM dNTP, and the following program: 1 cycle of 95°C for 1.5 min, 30 cycles of 95°C for 1 min/55°C for 1 min/72°C for 1 min, and 1 cycle of 72°C for 10 min The amplified target sequence was excised from a 1% agarose gel and the DNA extracted using the QiaexII kit (Qiagen, Mississauga, ON, Canada) The genes were then cloned into pCALnFLAG using the LIC procedure outlined by Stratagene (La Jolla, CA, USA), and then transformed into *E. coli* XL10 competent cells (Stratagene) The sequence for the *M. smegmatis* MAT has been deposited with Genbank under the accession number AY254892 The recombinant plasmid was purified from these cells using the QiaSpin miniprep kit (Qiagen), and the presence of the insert confirmed by digestion with NdeI and SacI and electrophoresis on a 1% agarose gel The plasmid from positive clones was transformed into *E. coli* BL21 DE3 CodonPlus RIL cells (Stratagene) for functional expression

The BL21 cells containing the recombinant plasmid were grown in LB liquid medium containing 50 μg/ml ampicillin and 50 μg/ml chloramphenicol at 37°C and 250 rpm until the cell density reached an A_{600nm} of 0.6 – 0.8 The culture was then cooled to 28°C and IPTG added to 1.0 mM before 2–5 hr of continued culture at 28°C and 250 rpm The cells were then pelleted by centrifugation at 3500 × g for 20 min at 4°C, and resuspended in a minimal volume of 10 mM HEPES pH 7.8/150 mM NaCl/1.0 mM DTT/1.0 mM imidazole/2.0 mM CaCl₂ before storage at -20°C The sample was thawed, sonicated on ice, and centrifuged at 3500 × g for 20 min at 4°C The resulting supernatant was loaded onto a 1.6 × 8.0 cm calmodulin-agarose column (Stratagene) equilibrated with the resuspension buffer The column was eluted with 10 mM HEPES pH 7.8/1.2 M NaCl/1.0 DTT/3.0 EGTA The eluted enzyme was concentrated to less than 5.0 ml using a 30 kDa molecular weight cut-off centrifugal filter (Pall Filtron; Mississauga, ON, Canada) The concentrated

enzyme was kept at 4°C for short term storage and at -20°C with 20% v/v glycerol for long term storage

The *M. tuberculosis* MAT was also subcloned into pET43 1a (Stratagene) for expression as an *E. coli* NusA fusion protein In addition to expression in *E. coli* BL21 DE3 RIL, the pCALnFlag and pET43 1a constructs were also expressed in *E. coli* BL21 DE3 pLysS (Stratagene), *E. coli* Rosetta DE3 pLysS (Novagen, Madison, WI, USA), or *E. coli* Origami DE3 pLysS (Novagen) Solubilisation and refolding of inclusion bodies was attempted using the Novagen protein refolding kit as per manufacturer's instructions

Protein concentration was determined using the Bio-Rad dye (Mississauga, ON, Canada) Protein samples were examined by electrophoresis on 10% SDS polyacrylamide gels followed by Coomassie R250 staining

Enzyme Assays

MAT activity was determined by incubating 10 μl of enzyme source with 100 μl of 100 mM Tris-HCl pH 8.2/20 mM MgCl₂/150 mM KCl/10 mM ATP/5 mM dithiothreitol/5 mM L-methionine for various lengths of time at 37°C The production of S-adenosylmethionine was then quantified by an HPLC method based on that of Yarlett and Bacchi [45] 100 μl of 0.1 M NaH₂PO₄ pH 2.65/8 mM heptane sulfonate/2% v/v CH₃CN (Buffer A) was added to the incubation mixture before the injection of 10 μl onto a 4.6 × 250 mm Econosphere C18 column (Alltech, Deerfield, IL, USA) The column was eluted with a 30 min gradient from 85% Buffer A and 15% Buffer B (0.15 M Na₂HPO₄ pH 3.25/8 mM heptane sulfonate/26% v/v CH₃CN) to 100% Buffer B The flow rate was 1.0 ml/min, and the reaction product was detected by ultraviolet spectrophotometry at 260 nm All separations were performed on an Agilent 1100 HPLC equipped with an autosampler, variable wavelength ultraviolet/visible spectrophotometric detector, and Chemstation operating system

For determining the kinetic constants for MAT, the enzyme was incubated as above with 0–4 mM substrate, 10 mM cosubstrate, 20 mM Mg²⁺, and 150 mM K⁺ The constants were determined by non-linear least-squared curve fitting using the Michaelis-Menton equation in the Scientist program (Micromath, Salt Lake City, UT, USA) For initial inhibitor screening, enzyme was incubated with 1 mM substrate, 10 mM cosubstrate, 20 mM Mg²⁺, 150 mM K⁺, and 10 mM inhibitor as described above Compounds which yielded greater than 70% inhibition of SAM production were rescreened using 0–10 mM inhibitor, 10 mM methionine, 0.5, 1.0, 2.0, or 3.0 mM ATP, 20 mM Mg²⁺, and 150 mM K⁺ The resulting data was examined using Dixon or Cornish-Bowden plots for competitive or uncompetitive inhibition respectively [46]

Growth Inhibition

Test compounds were serially diluted in a microtitre plate to yield 20 mM – 976 nM in a volume of 100 µl. A culture of *M. smegmatis* in mid-logarithmic growth was diluted in Middlebrook 7H9 medium to yield 2×10^5 cfu/ml. 100 µl of this diluted culture was then added to each well containing the test compounds before incubation at 30°C for 72 hr. Wells containing drug alone or bacteria alone were included as positive and negative controls. Microbial growth was measured using a 96-well spectrophotometer (Molecular Devices, Sunnyvale, CA, USA) at 650 nm. The MIC was determined as the lowest dilution which completely prevented microbial growth.

Phylogenetic Analysis

Additional MAT sequences were obtained from GenBank and the incomplete *M. avium* <http://www.tigr.org/tdb/mdb/mdbinprogress.html>, *M. bovis* http://www.sanger.ac.uk/Projects/M_bovis, and *M. marinum* http://www.sanger.ac.uk/Projects/M_marinum databases. All sequences were aligned using the Clustal algorithm and the BLOSUM sequence substitution table in the ClustalX program [47]. Aligned sequences were visualised with the Bioedit program [48]. The aligned sequences were then used with the ProtDist component of Phylip [49] to construct a distance matrix which was the basis for tree construction using neighbor-joining [16]. All trees were visualised using Treeview [50].

List of abbreviations used

SAM S-Adenosylmethionine

MAT Methionine Adenosyltransferase

HPLC High Performance Liquid Chromatography

IPTG Isopropylthiogalactopyranoside

MIC Minimum Inhibitory Concentration

Authors' contributions

BJB conceived the study, and performed the cloning, expression, and phylogenetic analysis. MHK performed the enzyme assays and inhibition studies.

Acknowledgements

The authors would like to acknowledge the technical assistance of Cynthia Radford with *Bacillus megaterium* expression. This work was funded in part by a Technology Innovation Fund Award from Defence R&D Canada to BJB.

Preliminary genome data was made available from The Institute for Genomic Research <http://www.tigr.org> for *Mycobacterium smegmatis* (funding by NIAID) and *M. avium* (funding by NIAID), and also from The Sanger Centre <http://www.sanger.ac.uk> for *M. bovis* (funding by Beowulf Genomics and MAFF) and *M. marinum* (funding by Beowulf Genomics).

References

- Dye C, Scheele S, Dolin P, Pathania V and Ravignone MC. **Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country.** WHO Global Surveillance and Monitoring Project JAMA 1999, **282**:677-86
- Besra GS and Chatterjee D. **Lipids and carbohydrates of *Mycobacterium tuberculosis*** In *Tuberculosis Pathogenesis, protection, and control* Edited by Bloom BR. Washington, ASM Press, 1994:285-306
- Parrish NM, Dick JD and Bishai WR. **Mechanisms of latency in *Mycobacterium tuberculosis*** Tr Microbiol 1998, **6**:107-12
- McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs WR Jr and Russell DG. **Persistence of *Mycobacterium tuberculosis* in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase** Nature 2000, **406**:735-8
- Marton LJ and Pegg AE. **Polyamines as targets for therapeutic intervention** Ann Rev Pharmacol Toxicol 1995, **35**:55-91
- Sarkar NK, Shankar S and Tyagi AK. **Polyamines exert regulatory control on mycobacterial transcription: a study using RNA polymerase from *Mycobacterium phlei*** Biochem Mol Biol Int 1995, **35**:1189-98
- Paulin LG, Brander EE and Poso HJ. **Specific inhibition of spermidine synthesis in *Mycobacteria* spp. by the dextro isomer of ethambutol** Antimicrob Ag Chemother 1985, **28**:157-9.
- Poso H, Paulin L and Brander E. **Specific inhibition of spermidine synthase from mycobacteria by ethambutol** Lancet 1983, **2**:1418
- Dubnau E, Chan J, Raynaud C, Mohan VP, Laneelle MA, Yu K, Quemard A, Smith I and Daffe M. **Oxygenated mycolic acids are necessary for virulence of *Mycobacterium tuberculosis* in mice** Mol Microbiol 2000, **36**:630-7
- Glickman MS, Cox JS and Jacobs WR Jr. **A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of *Mycobacterium tuberculosis*** Mol Cell 2000, **5**:717-27
- Schroeder BG and Barry CE 3rd. **The specificity of methyl transferases involved in trans mycolic acid biosynthesis in *Mycobacterium tuberculosis* and *Mycobacterium smegmatis*** Bioorg Chem 2001, **29**:164-77
- Huang CC, Smith CV, Glickman MS, Jacobs WR Jr and Sacchettini JC. **Crystal structures of mycolic acid cyclopropane synthases from *Mycobacterium tuberculosis*** J Biol Chem 2002, **277**:11559-69
- Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S and Barry CE 3rd. **Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence** Nature 1998, **393**:537-44
- Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M and Haft D. **Whole-genome comparison of *Mycobacterium tuberculosis* clinical and laboratory strains** J Bacteriol 2002, **184**:5479-90
- Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honore N, Garnier T, Churcher C and Harris D. **Massive gene decay in the leprosy bacillus** Nature 2001, **409**:1007-11
- Saitou N and Nei M. **The neighbor-joining method: a new method for reconstructing phylogenetic trees** Mol Biol Evol 1987, **4**:406-25.
- Takusagawa F, Kamitori S, Misaki S and Markham GD. **Crystal structure of S-adenosylmethionine synthetase** J Biol Chem 1996, **271**:136-47
- Lopez-Vara MC, Gasset M and Pajares MA. **Refolding and characterization of rat liver methionine adenosyltransferase from *Escherichia coli* inclusion bodies** Prot Expr Pur 2000, **19**:219-26
- Pan SH and Malcolm BA. **Reduced background expression and improved plasmid stability with pET vectors in BL21 (DE3)** Biotechniques 2000, **29**:1234-8
- Bessette PH, Aslund F, Beckwith J and Georgiou G. **Efficient folding of proteins with multiple disulfide bonds in the *Escherichia coli* cytoplasm** Proc Nat Acad Sci USA 1999, **96**:13703-8
- Davis GD, Elisee C, Newham DM and Harrison RG. **New fusion protein systems designed to give soluble expression in *Escherichia coli*** Biotech Bioeng 1999, **65**:382-8
- Rygas T and Hillen W. **Inducible high-level expression of heterologous genes in *Bacillus megaterium* using the regulatory elements of the xylose-utilization operon** Appl Microbiol Biotech 1991, **35**:594-599.

- 23 Chiang PK, Chamberlin ME, Nicholson D, Soubes S, Su X, Subramanian G, Lanar DE, Prigge ST, Scovill JP, Miller LH and Chou JY **Molecular characterization of *Plasmodium falciparum* S-adenosylmethionine synthetase** *Biochem J* 1999, **344(Pt 2):**571-6
- 24 Fraser CM, Gocayne JD, White O, Adams MD, Clayton RA, Fleischmann RD, Bult CJ, Kerlavage AR, Sutton G and Kelley JM **The minimal gene complement of *Mycoplasma genitalium*** *Science* 1995, **270:**397-403
- 25 Himmelreich R, Hilbert H, Plagens H, Pirkl E, Li BC and Herrmann R **Complete sequence analysis of the genome of the bacterium *Mycoplasma pneumoniae*** *Nucl Acids Res* 1996, **24:**4420-49.
26. Shigenobu S, Watanabe H, Hattori M, Sakaki Y and Ishikawa H **Genome sequence of the endocellular bacterial symbiont of aphids *Buchnera* sp.** *APS Nature* 2000, **407:**81-6
- 27 Grahm DE, Bock CL, Schalk-Hihi C, Lu ZJ and Markham GD **Identification of a highly diverged class of S-adenosylmethionine synthetases in the archaea** *J Biol Chem* 2000, **275:**4055-9
- 28 Butler WR and Guthertz LS **Mycolic acid analysis by high-performance liquid chromatography for identification of *Mycobacterium* species** *Clin Microbiol Rev* 2001, **14:**704-26
- 29 Korb M and Kredich NM **S-Adenosylmethionine synthetase from human lymphocytes. Purification and characterization** *J Biol Chem* 1985, **260:**3923-30
- 30 Mitsui K, Teraoka H and Tsukada K **Complete purification and immunochemical analysis of S-adenosylmethionine synthetase from bovine brain** *J Biol Chem* 1988, **263:**11211-6.
- 31 Reguera RM, Perez-Pertez Y, Ordonez C, Cubria JC, Tekwani BL, Balana-Fouce R and Ordonez D **S-adenosylmethionine synthesis in *Leishmania infantum* promastigotes** *Cell Biol Int* 1999, **23:**579-83
- 32 Yarlett N, Garofalo J, Goldberg B, Ciminelli MA, Ruggiero V, Sufrin JR and Bacchi CJ **S-adenosylmethionine synthetase in bloodstream *Trypanosoma brucei*** *Biochim Biophys Acta* 1993, **1181:**68-76
- 33 Reczkowski RS and Markham GD **Structural and functional roles of cysteine 90 and cysteine 240 in S-adenosylmethionine synthetase** *J Biol Chem* 1995, **270:**18484-90
- 34 Kelly GE, Scheibner A and Sheil AG **Effects of therapy with azathioprine and prednisolone and ultraviolet irradiation on mouse skin immune function and immune cell markers** *Immunol Cell Biol* 1987, **65(Pt 2):**153-61
- 35 Dalton A, Curtis D and Harrington CI **Synergistic effects of azathioprine and ultraviolet light detected by sister chromatid exchange analysis** *Cancer Genet Cytogenet* 1990, **45:**93-9
- 36 Berman JJ, Tong C and Williams GM **Toxicity of 6-thioguanine and 8-azaguanine to non-dividing liver cell cultures** *Cell Biol Toxicol* 1985, **1:**67-73
- 37 Rivest RS, Irwin D and Mandel HG **Inhibition of initiation of translation in L1210 cells by 8-azaguanine** *Biochem Pharmacol* 1982, **31:**2505-11.
- 38 Lavrador K, Guillerm D and Guillerm G **A new series of cyclic amino acids as inhibitors of S-adenosyl L-methionine synthetase** *Bioorg Med Chem Lett* 1998, **8:**1629-34
- 39 Lim H, Kappler F, Hai TT and Hampton A **Isozyme-specific enzyme inhibitors. 12. C- and N-methylmethionines as substrates and inhibitors of methionine adenosyltransferases of normal and hepatoma rat tissues** *J Med Chem* 1986, **29:**1743-8
- 40 Lavrador K, Allart B, Guillerm D and Guillerm G **A new series of S-adenosyl-L-methionine synthetase inhibitors** *J Enzyme Inhib* 1998, **13:**361-7
- 41 Kappler F and Hampton A **Approaches to isozyme-specific inhibitors. 17. Attachment of a selectivity-inducing substituent to a multisubstrate adduct. Implications for facilitated design of potent, isozyme-selective inhibitors** *J Med Chem* 1990, **33:**2545-51.
- 42 Vrudhula VM, Kappler F and Hampton A **Isozyme-specific enzyme inhibitors. 13. S-[5'(R)-[(N-triphosphoamino)methyl]adenosyl]-L-homocysteine, a potent inhibitor of rat methionine adenosyltransferases** *J Med Chem* 1987, **30:**888-94
- 43 Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W and Lipman DJ **Gapped BLAST and PSI-BLAST: a new generation of protein database search programs** *Nucl Acids Res* 1997, **25:**3389-402
- 44 Aslanidis C and de Jong PJ **Ligation-independent cloning of PCR products (LIC-PCR)** *Nucl Acids Res* 1990, **18:**6069-74.
- 45 Yarlett N and Bacchi CJ **Effect of DL-alpha-difluoromethylornithine on methionine cycle intermediates in *Trypanosoma brucei*** *Mol Biochem Parasitol* 1988, **27:**1-10
- 46 Cornish-Bowden A **A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors** *Biochem J* 1974, **137:**143-4
- 47 Thompson JD, Higgins DG and Gibson TJ **CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice** *Nucl Acids Res* 1994, **22:**4673-80
- 48 Hall TA **Bioedit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT** *Nucl Acids Symp Ser* 1999, **41:**95-98
- 49 Felsenstein J **PHYLIP - phylogeny inference package (version 3.2)** *Cladistics* 1989, **5:**164-166
- 50 Page RD **TreeView: an application to display phylogenetic trees on personal computers** *Comp Appl Biosci* 1996, **12:**357-8
- 51 Yocum RR, Perkins JB, Howitt CL and Pero J **Cloning and characterization of the metE gene encoding S-adenosylmethionine synthetase from *Bacillus subtilis*** *J Bacteriol* 1996, **178:**4604-10
- 52 Boyle SM, Markham GD, Hafner EW, Wright JM, Tabor H and Tabor CW **Expression of the cloned genes encoding the putrescine biosynthetic enzymes and methionine adenosyltransferase of *Escherichia coli* (speA, speB, speC and metK)** *Gene* 1984, **30:**129-36
- 53 Thomas D and Surdin-Kerjan Y **SAMI, the structural gene for one of the S-adenosylmethionine synthetases in *Saccharomyces cerevisiae*. Sequence and expression** *J Biol Chem* 1987, **262:**16704-9
- 54 Horikawa S and Tsukada K **Molecular cloning and nucleotide sequence of cDNA encoding the human liver S-adenosylmethionine synthetase** *Biochem Int* 1991, **25:**81-90

Publish with **Bio Med Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime"

Sir Paul Nurse, Cancer Research UK

Your research papers will be

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here

http://www.biomedcentral.com/info/publishing_adv.asp



BioMed Central

#519803

CA022802